Last week, CSL Limited CEO Paul Perreault represented the CoVIg-19 Plasma Alliance at a White House roundtable with federal officials. The topic was donating plasma and the potential of plasma-based treatments for COVID-19. Here’s a look at two approaches – convalescent plasma infusions and hyperimmune globulin. These two treatments differ in the way they’re processed, the scale at which they can be produced, how long they last on the shelf, their effectiveness and their expected potency.
This website uses cookies to improve user experience. By continuing to use this website, you consent to our use of these cookies. To learn more about how we use and manage cookies, see our Privacy Policy and Cookie Policy.